Sunshine Biopharma (SBFM) Liabilities and Shareholders Equity (2010 - 2026)

Sunshine Biopharma's Liabilities and Shareholders Equity history runs 16 years deep, the most recent figure standing at $27.9 million for Q1 2026.

• Quarterly Liabilities and Shareholders Equity fell 4.31% year-over-year to $27.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $121.5 million (up 1.98% YoY) and the FY2025 annual result came in at $30.1 million, down 1.57% from the prior year.
• Liabilities and Shareholders Equity was $27.9 million for Q1 2026 at Sunshine Biopharma, down from $30.1 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $42.0 million in Q2 2022 and bottomed at $13.4 million in Q1 2022.
• A 5-year average of $29.9 million and a median of $29.3 million in 2024 frame the typical range for Liabilities and Shareholders Equity.
• Annual changes were most pronounced in 2022 — Liabilities and Shareholders Equity soared 2210.92% — and 2023, when it sank 32.34%.
• Sunshine Biopharma's Liabilities and Shareholders Equity stood at $29.2 million in 2022, then retreated by 6.49% to $27.3 million in 2023, then climbed by 11.75% to $30.6 million in 2024, then retreated by 1.57% to $30.1 million in 2025, then decreased by 7.14% to $27.9 million in 2026.
• Business Quant data shows SBFM's Liabilities and Shareholders Equity at $27.9 million in Q1 2026, $30.1 million in Q4 2025, and $31.5 million in Q3 2025.